Pregnancy does not prevent disease re-activation after natalizumab suspension in patients with multiple sclerosis (S20.003)

Objective: To assess multiple sclerosis (MS) disease activity during pregnancy after natalizumab exposure (NE) and the impact of natalizumab exposure (NE) on pregnancy outcomes. Background: While the risk of disease re-activation after natalizumab suspension is widely acknowledged, little is known on disease activity during pregnancy occurring after suspension of natalizumab in MS patients. In hypothesis, since gestational period is related to a reduction of relapse-rate, a “protection” from disease re-activation could be expected. Design/Methods: we recruited NE pregnancies in MS patients prospectively followed-up in 13 Italian MS Centres, in the period 2010-2013. Exposure to natalizumab was defined as suspension of the drug 0.3). Conclusions: in our study pregnancy did not protect from disease re-activation after natalizumab suspension in MS patients. The risk of relapses during pregnancy should be taken into account in the counselling of natalizumab-treated MS patients contemplating pregnancy. Disclosure: Dr. Amato has received personal compensation for activities with Biogen Idec, Merck, Serono, Inc., Bayer, Novartis, Teva Neuroscience, Sanofi-Aventis, Genzyme, and Almirall as a speaker and/or advisor. Dr. Amato has received research support from Biogen I Dr. Hakiki has nothing to disclose. Dr. Pasto has nothing to disclose. Dr. Giannini has received personal compensation for activities with Biogen Idec. Dr. Razzolini has nothing to disclose. Dr. Tortorella has nothing to disclose. Dr. D9Onghia has nothing to disclose. Dr. Trojano has received personal compensation for activities with Sanofi-Aventis Pharmaceuticals, Inc., Biogen Idec, Novartis and Bayer Schering Pharma as a consultant and/or speaker. Dr. Cocco has nothing to disclose. Dr. Melis has nothing to disclose. Dr. Marrosu has received personal compensation for activities with Biogen Idec and Merck Serono as a speaker. Dr. Di Tommaso has received research support from Serono. Dr. Farina has nothing to disclose. Dr. Lugaresi has received personal compensation for activities with Bayer Schering, Biogen Idec, Merck Serono, Genzyme, Sanofi-Aventis Pharmaceuticals, and Teva Neuroscience. Dr. Annovazzi has received personal compensation for activities with Biogen Idec, Novartis, and Teva Pharmaceutical as a consultant, speaker, and/or advisor. Dr. Ghezzi has received personal compensation for activities with Merck Serono, Novartis, Biogen Idec, Teva, Bayer Schering, Sanofi-Genzyme, Serono, and Almirall as an advisory board member and/or speaker. Dr. Gasper has received personal compensation for activities with Merck Serono, Biogen Idec, Teva, Novartis, Genzyme, and Bayer Sheering as a speaker. Dr. Iudice has nothing to disclose. Dr. Fantozzi has received personal compensation for activities with Bayer Shering, Biogen Idec, Merck-Serono, Sanofi-Aventis, and Novartis as a speaker. Dr. Bellantonio has received personal compensation for activities with Bayer Shering Pharma, Biogen Idec, Merck Serono, Sanofi, and Novartis as a speaker. Dr. Messina has nothing to disclose. Dr. Patti has received personal compensations for activities with Merck Serono, Bayer Schering Pharma, and Dompe Biotec. Dr. Masera has nothing to disclose. Dr. Cavalla has nothing to disclose. Dr. Protti has nothing to disclose. Dr. Rossi has nothing to disclose. Dr. Totaro has received personal compensation for activities with Bayer Shering Pharma, Biogen Idec, Merck Serono, Sanofi-Aventis Pharmaceuticals, Inc., Teva Neuroscience, and Novartis as a speaker and/or consultant. Dr. De Giglio has nothing to disclose. Dr. Pozzilli has received personal compensation for activities with Actelion, Biogen Idec, Genzyme, Merck Serono, Novartis, and Teva Neuroscience as a consultant. Dr. Portaccio has received personal compensation for activities with Biogen Idec, Bayer, and Merck Serono. Dr. Portaccio has received research support from Biogen Idec, Bayer, Merck Serono, and Sanofi-Aventis.